Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.

Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, Heresco-Levy U, Carpenter WT.

Am J Psychiatry. 2007 Oct;164(10):1593-602.

PMID:
17898352
2.

A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia.

Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA, Hayden DL, McCarley R, Coyle JT.

Arch Gen Psychiatry. 1999 Jan;56(1):21-7.

PMID:
9892252
3.

Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study.

Goff DC, Cather C, Gottlieb JD, Evins AE, Walsh J, Raeke L, Otto MW, Schoenfeld D, Green MF.

Schizophr Res. 2008 Dec;106(2-3):320-7. doi: 10.1016/j.schres.2008.08.012. Epub 2008 Sep 16.

4.

Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.

Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE.

Arch Gen Psychiatry. 2005 Nov;62(11):1196-204.

PMID:
16275807
5.

A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia.

Weiser M, Heresco-Levy U, Davidson M, Javitt DC, Werbeloff N, Gershon AA, Abramovich Y, Amital D, Doron A, Konas S, Levkovitz Y, Liba D, Teitelbaum A, Mashiach M, Zimmerman Y.

J Clin Psychiatry. 2012 Jun;73(6):e728-34. doi: 10.4088/JCP.11m07031.

PMID:
22795211
6.

D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study.

van Berckel BN, Evenblij CN, van Loon BJ, Maas MF, van der Geld MA, Wynne HJ, van Ree JM, Kahn RS.

Neuropsychopharmacology. 1999 Aug;21(2):203-10.

7.

Effects of D-cycloserine on negative symptoms in schizophrenia.

Duncan EJ, Szilagyi S, Schwartz MP, Bugarski-Kirola D, Kunzova A, Negi S, Stephanides M, Efferen TR, Angrist B, Peselow E, Corwin J, Gonzenbach S, Rotrosen JP.

Schizophr Res. 2004 Dec 1;71(2-3):239-48. Review.

PMID:
15474895
8.

Placebo-controlled trial of glycine added to clozapine in schizophrenia.

Evins AE, Fitzgerald SM, Wine L, Rosselli R, Goff DC.

Am J Psychiatry. 2000 May;157(5):826-8.

PMID:
10784481
9.

D-cycloserine added to clozapine for patients with schizophrenia.

Goff DC, Tsai G, Manoach DS, Flood J, Darby DG, Coyle JT.

Am J Psychiatry. 1996 Dec;153(12):1628-30.

PMID:
8942463
10.
11.

d-Cycloserine augmentation of cognitive remediation in schizophrenia.

Cain CK, McCue M, Bello I, Creedon T, Tang DI, Laska E, Goff DC.

Schizophr Res. 2014 Mar;153(1-3):177-83. doi: 10.1016/j.schres.2014.01.016. Epub 2014 Jan 30.

12.

Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.

de Lucena D, Fernandes BS, Berk M, Dodd S, Medeiros DW, Pedrini M, Kunz M, Gomes FA, Giglio LF, Lobato MI, Belmonte-de-Abreu PS, Gama CS.

J Clin Psychiatry. 2009 Oct;70(10):1416-23. doi: 10.4088/JCP.08m04935gry. Erratum in: J Clin Psychiatry. 2011 Aug;72(8):1157.

PMID:
19906345
13.

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.

Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M.

Arch Gen Psychiatry. 1999 Jan;56(1):29-36.

PMID:
9892253
14.

Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia.

Goff DC, Tsai G, Manoach DS, Coyle JT.

Am J Psychiatry. 1995 Aug;152(8):1213-5.

PMID:
7625475
15.

Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.

Lane HY, Lin CH, Green MF, Hellemann G, Huang CC, Chen PW, Tun R, Chang YC, Tsai GE.

JAMA Psychiatry. 2013 Dec;70(12):1267-75. doi: 10.1001/jamapsychiatry.2013.2159.

PMID:
24089054
16.

The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial.

Lerner V, Miodownik C, Gibel A, Sirota P, Bush I, Elliot H, Benatov R, Ritsner MS.

J Clin Psychiatry. 2013 Dec;74(12):1224-32. doi: 10.4088/JCP.12m08160.

PMID:
24434091
17.

Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial.

Keefe RS, Malhotra AK, Meltzer HY, Kane JM, Buchanan RW, Murthy A, Sovel M, Li C, Goldman R.

Neuropsychopharmacology. 2008 May;33(6):1217-28. Epub 2007 Jul 11.

18.

A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.

Kane JM, Correll CU, Goff DC, Kirkpatrick B, Marder SR, Vester-Blokland E, Sun W, Carson WH, Pikalov A, Assunção-Talbott S.

J Clin Psychiatry. 2009 Oct;70(10):1348-57. doi: 10.4088/JCP.09m05154yel.

PMID:
19906340
19.

Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.

Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG.

Arch Gen Psychiatry. 1997 Jun;54(6):549-57.

PMID:
9193196
20.

A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia.

Buchanan RW, Keefe RS, Lieberman JA, Barch DM, Csernansky JG, Goff DC, Gold JM, Green MF, Jarskog LF, Javitt DC, Kimhy D, Kraus MS, McEvoy JP, Mesholam-Gately RI, Seidman LJ, Ball MP, McMahon RP, Kern RS, Robinson J, Marder SR.

Biol Psychiatry. 2011 Mar 1;69(5):442-9. doi: 10.1016/j.biopsych.2010.09.052. Epub 2010 Dec 8.

Items per page

Supplemental Content

Write to the Help Desk